Insiders Trading HALO, PSTR, EMC

By Jonathan Moreland, founder of Insider Insights and author of Profit From Legal Insider Trading.

NEW YORK ( TheStreet) -- Which insiders are selling and buying chunks of stocks?

Below are lists of the top 10 mainly open-market insider purchases and sales filed at the Securities and Exchange Commission Monday, February 13, 2012 as ranked by dollar value. Company executives and directors are in the best position to assess the attractiveness of their firms' shares, and here is how many of them are voting their wallets! Please note, however, that these are factual lists, not buy and sell recommendations. Dollar value is only one metric to assess the importance of an insider transaction.

Halozyme Therapeutics (HALO) Kirk Randal J DIR,BO 1,360,000 $14,429,600
Postrock Energy (PSTR) Edelman And Guill Energy L P DIR,BO 2,180,233 $7,500,002
Onteco (ONTC) Kammona Amir BO 15,493,000 $2,155,040
Dominion Resources (D) Kington Mark J DIR 25,000 $1,245,500
RAIT Financial Trust (RAS) Rima Senvest Management BO 187,322 $1,065,677
Post Holdings (POST) Danforth William H DIR 25,000 $652,413
Parkway Properties (PKY) Heistand James R PR,CEO
60,000 $603,734
Brightpoint (CELL) Smith Michael L DIR 25,000 $250,000
Knight Capital Group (KCG) Hoffman Peter J MD 19,000 $248,596
First Opportunity Fund (FOFI) Lola Brown Trust 1b BO 24,038 $160,965
Calpine (CPN) Spo Advisory BO 33,600,000 $523,152,000
Google (GOOG) Page Lawrence CEO,DIR
27,778 $17,005,370
Autonation (AN) Bill And Melinda Gates Foundation O 353,200 $13,004,859
Emc Corp (EMC) Tucci Joseph M CB,PR
396,415 $10,405,894
Lululemon Athletica (LULU) Wilson Dennis J DIR,BO 85,000 $5,567,618
Prudential Financial (PRU) Strangfeld John R Jr CEO,CB
64,876 $3,897,750
Simpson Manufacturing (SSD) Simpson Barclay DIR,BO 78,874 $2,527,273
Volterra Semiconductor (VLTR) Staszak Jeffrey PR,CEO
75,000 $2,400,000
Ultimate Software (ULTI) Scherr Scott CB,PR
31,746 $2,112,276
RenaissanceRe Holdings (RNR) Branagan Ian D VP 29,000 $2,111,080

Key to Titles: A=Assistant, AI=Affiliated Investor, AO=Accounting Officer, BD=Business Development, BO=Beneficial Owner, CAO=Chief Accounting Officer, CB=Chairman, CCO=Chief Compliance Officer, CEO=Chief Executive Officer, CFO=Chief Financial Officer, CIO=Chief Information Officer, CO=Compliance Officer, COO=Chief Operating Officer, CT=Controller, CTO=Chief Technology Officer, DIR=Director, EVP=Executive Vice President, F=Founder, FO=Financial Officer, GC=General Counsel, HR=Human Resources, IO=Information Officer, IR=Investor Relations, LO=Legal Officer, MD=Managing Director, O=Officer, OO=Operating Officer, PR=President, PT=Partner, REL=Relative of an insider, SEC=Secretary, SH=Shareholder, SO=Sales Officer, TO=Technology Officer, TR=Treasurer, TT=Trustee, VCB=Vice Chairman, VP=Vice President, X=Ex Officer or other title displayed.
Jonathan Moreland is the founder of, which produces a weekly newsletter and offers professional screening and alerting tools to analyze a proprietary, real-time insider data feed. He is also the principal of Insider Asset Management, a registered investment advisor in New York. Mr. Moreland has been analyzing insider data professionally for two decades and has been a contributor to since 2001. A fundamental analyst with an MBA in finance, Mr. Moreland long ago identified insider data as an excellent first screen to determine where to focus his research efforts. He is quoted frequently in the media for his insider analysis and stock recommendations stemming from it. He is also author of Profit From Legal Insider Trading.

Under no circumstances does the information in this column represent a recommendation to buy or sell stocks. While he cannot provide investment advice or recommendations, Moreland appreciates your feedback; click here to send him an email.

If you liked this article you might like

Strong Action in Individual Stocks Starts to Feel a Bit Frothy

Good Stocks Are There for the Picking

There Are Good Opportunities in Stock Picking

Halozyme Jumps on Immuno-Oncology Deal with Bristol-Myers

Biotech Movers: Lion Biotechnologies, XBiotech, Halozyme